News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adenosine Therapeutics Initiates Phase Ib Clinical Study With ATL146e



10/25/2006 10:50:33 AM

CHARLOTTESVILLE, Va., Oct. 25 /PRNewswire/ -- Adenosine Therapeutics, LLC, a leading adenosine drug discovery and development company, announced today it has initiated a two-part Phase Ib study in humans to evaluate apadenoson (ATL146e), a potent selective adenosine A2A agonist, as an anti-inflammatory agent.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES